Business Wire

GSMA Announces Completion of First European NB-IoT Roaming Trial

Del

The GSMA today announced that mobile operators Deutsche Telekom and Vodafone Group have successfully completed the first international roaming trial in Europe using licensed NB-IoT technology. The service will ensure seamless coverage and service continuity for millions of connections using Low Power Wide Area (LPWA) networks. The trial was performed using global SIMs from Deutsche Telekom on Vodafone Spain’s network and global Vodafone SIMs on T-Mobile Austria’s network and commercial NB-IoT modules. The trials will also provide guidance to other operators in delivering a consistent level of implementation.

“The success of these trials is an important milestone in the development of a sustainable roaming environment for Mobile IoT networks, showcasing their capabilities as well as ensuring consistent service across geographical boundaries,” said Alex Sinclair, Chief Technology Officer, GSMA. “The market has matured considerably in a very short time and we anticipate that this will be the year that Mobile IoT scales. Undoubtedly this is because only licensed, managed mobile services can provide the secure low power connection that can meet future demand.”

Roaming is particularly important to manufacturers deploying LPWA devices on a global basis and looking to benefit from economies of scale. It is also critical for use cases such as logistics tracking, which may involve containers crossing numerous international borders on a single trip, as well as for devices that may be manufactured in one country but deployed in another, such as smart meters. The roaming test cases were jointly developed by Deutsche Telekom and Vodafone and include important power saving features such as Power Saving Mode (PSM), Long Periodic Tracking Area Update (TAU) and various throughput and round-trip-time measurements. Underscored by the success of these trials, the industry is working to accelerate the adoption of NB-IoT roaming around the world.

“Deutsche Telekom has successfully introduced and developed NB-IoT networks across most of its European footprint and we are very pleased to see the ecosystem rapidly expanding,” says Ingo Hofacker, responsible for the IoT business in the Deutsche Telekom Group. “First commercial offers are available on a national basis already, but now, operators need to satisfy customer demand for international coverage and service continuity as well.”

Vodafone director of IoT Stefano Gestaut said, “This development shows the successful evolution of the technology and I am confident that it will lead to a raft of new applications for NB-IoT, such as the cold chain monitoring of goods across borders.

The GSMA’s Mobile IoT Initiative has helped standardise licenced LPWA technologies including NB-IoT and LTE-M in 3GPP and to date, 29 mobile operators have launched 51 commercial Mobile IoT networks around the world. The GSMA is working to accelerate the adoption of Mobile IoT through 36 Open IoT Labs, enabling operators, module vendors and application providers to develop LPWA devices and applications for a wide variety of verticals. The GSMA’s Mobile IoT Innovators Community is supported by an expanding community of over 900 organisations. According to GSMA Intelligence forecasts, by 2025 there will be 3.1 billion cellular IoT connections, including 1.8 billion licensed LPWA connections.

The GSMA Mobile IoT Initiative is backed by over 70 global mobile operators, device makers and chipset, module and infrastructure companies worldwide and helped the industry to standardise and deliver commercial Low Power Wide Area technologies in licensed spectrum, in particular the complementary technologies NB-IoT and LTE-M. These networks are designed to support mass market IoT applications across a wide variety of applications such as industrial asset tracking, safety monitoring or water and gas metering, that are low cost, use low data rates, require long battery lives and often operate in remote locations.

For further information on the Mobile IoT initiative visit: www.gsma.com/iot/mobile-iot-initiative/.

-ENDS-

About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

Contact information

For the GSMA
Beau Bass
+44 79 7662 4962
beau.bass@webershandwick.com
or
GSMA Press Office
pressoffice@gsma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 05:00Pressemelding

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 04:05Pressemelding

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth15.8.2018 23:40Pressemelding

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 22:37Pressemelding

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 17:43Pressemelding

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.

Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovation15.8.2018 17:05Pressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has been honored with a Stevie® Award in the Innovation in Customer Service Management, Planning & Practice category for its ultra-responsive, premium level service in the Asia-Pacific region. This honor marks the Company’s 12th Stevie Award win this year, and the second consecutive year the Company has been recognized by the Asia-Pacific Stevie Awards. Rimini Street recently earned Stevie Awards in several categories, including Company of the Year from the 2018 American Business Awards® and Customer Service Department of the Year from the 2018 Stevie Awards for Sales & Customer Service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005580/en/ Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovat